Differential activation of platelets from normal and allergic ponies by PAF and ADP

Inflammation Research

Volumn 49, Issue 5, 2000, Pages 224-230

  Bailey, S R ^a   Andrews, M J ^a   Elliott, J ^a   Cunningham, F M ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

5 HT release; Aggregation; Equine platelet; PAF and ADP; Thromboxane production

Indexed keywords

ADENOSINE DIPHOSPHATE; ICOSANOID; SEROTONIN; THROMBOCYTE ACTIVATING FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; HISTAMINE RELEASE; HORSE; NONHUMAN; PATHOGENESIS; SEROTONIN RELEASE; SIGNAL TRANSDUCTION; SKIN ALLERGY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID; ADENOSINE DIPHOSPHATE; ANIMALS; DERMATITIS, CONTACT; EICOSANOIDS; HORSE DISEASES; HORSES; HYPERSENSITIVITY, IMMEDIATE; PLATELET ACTIVATING FACTOR; PLATELET ACTIVATION; SEASONS; SEROTONIN; SIGNAL TRANSDUCTION; THROMBOXANE B2;

EID: 0034080222     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050583     Document Type: Article

References (35)

1. [1] Foster AP, Cunningham FM. The pathogenesis and immunopharmacology of equine insect hypersensitivity. Adv Vet Dermatol 1998; 3: 178-89.
2. [2] Riek RF. Studies on allergic dermatitis ('Queensland Itch') of the horse: Description, distribution, symptoms and pathology. Austr Vet J 1953; 29: 177-84.
3. [3] Kurotaki T, Narayama K, Oyamada T, Yoshikawa H, Yoshimkawa T. Immunopathological study on equine insect hypersensitivity ('Kasen') in Japan. J Comp Path 1994; 110: 145-52.
4. [4] Herd CM, Page CP. Platelets. In: Kay AB, editor. Allergy and Allergic Disease. Oxford: Blackwell Scientific Publications, 1997: 214-27.
5. [5] Suquet CM, Leid RW. Aggregation of equine platelets by PAF (platelet activating factor). Inflammation 1985; 7: 197-203.
6. [6] Foster AP, Lees P, Andrews MJ, Cunningham FM. Effects of WEB 2086, an antagonist to the receptor for platelet activating factor (PAF), on PAF-induced responses in the horse. Equine Vet J 1992; 24: 203-7.
7. [7] Heath MF, Evans RJ, Poole AW, Hayes LJ, McEvoy RJ, Littler RM. The effects of aspirin and paracetamol on the aggregation of equine platelets. J Vet Pharmacol Ther 1994; 17: 374-378.
8. [8] Foster AP, Lees P, Cunningham FM. Actions of PAF receptor antagonists in horses with allergic skin disease. Inflamm Res 1995; 44: 412-7.
9. [9] Mannaioni PF, Di Bello MG, Masini E. Platelets and inflammation: Role of platelet-derived growth factor, adhesion molecules and histamine. Inflamm Res 1997; 46: 4-18.
10. [10] Masini E, Di Bello MG, Raspanti S, Fomusi Ndisang J, Baronit R, Cappugi P et al. The role of histamine in platelet aggregation by physiological and immunological stimuli. Inflamm Res 1998; 47: 211-20.
11. [11] Riek RF. Studies on allergic dermatitis (Queensland Itch) of the horse: the origin and significance of histamine in the blood and its distribution in the tissues. Austr J Agri Res 1955; 6: 161-70.
12. [12] Hilger RA, Neuber K., Konig W. Conversion of leukotriene A4 by neutrophils and platelets from patients with atopic dermatitis. Immunology 1991; 74: 689-95.
13. [13] Neuber K, Hilger RA, Konig W. Differential increase in 12-HETE release and CD29/CD49f expression of platelets from normal donors and from patients with atopic dermatitis. Int Arch Allergy Immunol 1992; 98: 339-42.
14. [14] Ring J, Dorsch W. Altered releasability of vasoactive mediator secreting cells in atopic eczema. Acta Derm Venereol Suppl (Stockh) 1985; 114: 9-23.
15. [15] Meyers KM, Lindner C, Grant B. Characterisation of equine platelet aggregation response. Am J Vet Res 1979; 40: 260-4.
16. [16] Jarvis GE, Evans RJ, Heath MF. The role of ADP in endotoxin-induced equine platelet activation. Eur J Pharmacol 1996; 315: 203-12.
17. [17] Meyers KM, Holmsen H, Seachord CL. Comparative study of platelet dense granule constituents. Am J Physiol 1982; 243: R454-61.
18. [18] Foster AP, Lees P, Cunningham FM. Platelet activating factor (PAF) mimics antigen-induced cutaneous inflammatory responses in sweet itch horses. Vet Immunol Immunopathol 1995; 44: 115-28.
19. [19] Lees P, Ewins CP, Taylor JBO, Sedgwick AD. Serum thromboxane in the horse and its inhibition by aspirin, phenylbutazone and flunixin. Br Vet J 1987; 143: 462-76.
20. [20] Bailey SR, Elliott J. Plasma 5-hydroxytryptamine constricts equine digital blood vessels in vitro: implications for the pathogenesis of acute laminitis. Equine Vet J 1998; 30: 124-30.
21. [21] Audera C, Rocklin R, Vaillancourt R, Jakubowski JA, Deykin D. Altered arachidonic acid metabolism and platelet size in atopic subjects. Clin Immunol Immunopathol 1988; 46: 352-59.
22. [22] Ablett JM, Fairbairn SM, Page CP, Lees P, Cunningham FM. Influence of antigen challenge on platelet responsiveness in horses with chronic obstructive pulmonary disease. Equine Vet J 1997; 29, 382-6.
23. [23] Cambridge H, Lees P, Hooke RE, Russell CS. Antithrombotic actions of aspirin in the horse. Equine Vet J 1991; 23: 123-7.
24. [24] Mohammad SF, Anderson WH, Smith JB, Chuang HY, Mason RG. Effects of heparin on platelet aggregation and release and thromboxane A2 production. Am J Pathol 1981; 104: 132-41.
25. [25] Marcus AJ, Safier LB, Ullman HL, Wong KTH, Broekman J, Weksler BB et al. Effects of aceryl glyceryl ether phosphorylcholine on human platelet function in vitro. Blood 1981; 5: 1027-31.
26. [26] Kawahara Y, Yamanishi J, Tsunemitsu M, Fukuzaki H. Protein phosphorylation and diglyceride production during serotonin release induced by epinephrine plus ADP in human platelets. Thromb Res 1983; 30: 477-85.
27. [27] Rosenblum WI, Nelson GH, Cockrell CS, Ellis EF. Some properties of mouse platelets. Thromb Res 1983; 30: 347-55.
28. [28] Levy-Toledano S, Caen JP, Breton-Gorius J, Rendu F, CywinerGolenzer C, Dupuy E et al. Gray platelet syndrome: alpha-granule deficiency. Its influence on platelet function. J Lab Clin Med 1981; 98: 831-48.
29. [29] Dragan YP, Ellis EF. Effect of adenine nucleotides on cyclooxygenase and lipoxygenase enzyme products of arachidonic acid in human platelets. Biochem Pharmacol 1990; 39: 27-32.
30. [30] Korth R, Riess H, Brehm G, Hiller E. Unsaturated platelet-activating factor: influence on aggregation, serotonin release and thromboxane synthesis of human thrombocytes. Thromb Res 1986; 41: 699-706
31. [31] Macconi D, Morzenti G, Livio M, Morelli C, Cassina G, Remuzzi, G. Acetyl glycerylphosphorylcholine aggregates human platelets through two distinct pathways, both dependent on arachidonic acid metabolism. Lab Invest 1985; 52: 159-68.
32. [32] Shaw JO, Klusick SJ, Hanahan DJ. Activation of rabbit platelet phospholipase and thromboxane synthesis by 1-0-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet activating factor). Biochim Biophys Acta 1981; 663: 222-9.
33. [33] Chesney CM, Pifer DD, Byers LW, Muirhead EE. Effect of platelet-activating factor (PAF) on human platelets. Blood 1982; 59: 582-5.
34. [34] Kloprogge E, De Haas GH, Gorter G, Akkerman JWN. Stimulus-response coupling in human platelets. Evidence against a role of PAF-acether in the 'third pathway'. Thromb Res 1983; 30: 107-12.
35. [35] Best LC, Holland TK, Jones PB, Russell RG. The interrelationship between thromboxane biosynthesis, aggregation and 5-hydroxytryptamine secretion in human platelets in vitro. Thromb Haemost 1980; 43: 38-40.